In a report released today, David Nierengarten from Wedbush maintained a Buy rating on Generation Bio (GBIO – Research Report), with a price target of $5.00. The company’s shares closed yesterday at $2.84.
Nierengarten covers the Healthcare sector, focusing on stocks such as Fate Therapeutics, Oric Pharmaceuticals, and Xencor. According to TipRanks, Nierengarten has an average return of 11.3% and a 43.24% success rate on recommended stocks.
Currently, the analyst consensus on Generation Bio is a Moderate Buy with an average price target of $8.00.
The company has a one-year high of $6.98 and a one-year low of $0.86. Currently, Generation Bio has an average volume of 242.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Generation Bio (GBIO) Company Description:
Generation Bio Co is a genetics medicine company which is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.
Read More on GBIO:
- Generation Bio Announces Recent Business Highlights and First Quarter 2024 Financial Results
- Generation Bio presents preclinical data on iqDNA, ctLNP platforms
- Generation Bio Announces the Acceptance of Five Abstracts and an Invited Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
- Third Harmonic Bio appoints McDonough to board of directors
